Register for our S/EIS Fund

According to the WHO, antibiotic resistance is one of the biggest threats to global health, food security, and development today. Also, a growing number of infections such as pneumonia, tuberculosis, gonorrhea, and salmonellae are becoming harder to treat as the antibiotics used to treat them become less effective.

In this ChaiTime, Aleks quizzed some of the most innovative biotech companies in the space from both Cambridge and Oxford who are one of the pioneers/leaders in this battle.

The panelists
Paul Finn CEO at Oxford University Spinout, Oxford Drug Design

Ajay Mistry CEO at AI and antibiotics discovery start-up, Oppilotech

Ken Bradley Global Head, Infectious Disease Discovery at Roche pharmaceutical Research and Early Development (pRED)

Ankit Mahadevia CEO of NASDAQ listed, Spero Therapeutics

Register for Invitations